Sanofi’s $1.7B rare disease bet beats CSL’s Zemaira in phase 2 face-off
Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. In a midstage study, efdoralprin alfa beat the standard of care on primary and key…
Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. In a midstage study, efdoralprin alfa beat the standard of care on primary and key…